- 関
- vascular endothelial growth factor D
WordNet
- the 4th letter of the Roman alphabet (同)d
PrepTutorEJDIC
- deuteriumの化学記号
- (おもに人称代名詞・固有名詞(人名),thereの後で)had, wouldの短縮形 / (疑問文でwhere,what,whenの後で)didの短縮形;Where'd he go?=Where did he go?
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/05/17 20:12:59」(JST)
[Wiki en表示]
C-fos induced growth factor (vascular endothelial growth factor D) |
Available structures |
PDB |
Ortholog search: PDBe, RCSB |
List of PDB id codes |
2XV7
|
|
|
Identifiers |
Symbols |
FIGF ; VEGF-D; VEGFD |
External IDs |
OMIM: 300091 MGI: 108037 HomoloGene: 3288 GeneCards: FIGF Gene |
Gene ontology |
Molecular function |
• platelet-derived growth factor receptor binding
• vascular endothelial growth factor receptor binding
• growth factor activity
• chemoattractant activity
• protein homodimerization activity
• vascular endothelial growth factor receptor 3 binding
|
Cellular component |
• extracellular region
• extracellular space
• membrane
• platelet alpha granule lumen
|
Biological process |
• angiogenesis
• platelet degranulation
• blood coagulation
• cell proliferation
• positive regulation of cell proliferation
• cell differentiation
• platelet activation
• vascular endothelial growth factor receptor signaling pathway
• positive chemotaxis
• induction of positive chemotaxis
• positive regulation of cell division
• positive regulation of mast cell chemotaxis
|
Sources: Amigo / QuickGO |
|
RNA expression pattern |
|
More reference expression data |
Orthologs |
Species |
Human |
Mouse |
|
Entrez |
2277 |
14205 |
|
Ensembl |
ENSG00000165197 |
ENSMUSG00000031380 |
|
UniProt |
O43915 |
P97946 |
|
RefSeq (mRNA) |
NM_004469 |
NM_010216 |
|
RefSeq (protein) |
NP_004460 |
NP_034346 |
|
Location (UCSC) |
Chr X:
15.36 – 15.4 Mb |
Chr X:
164.37 – 164.4 Mb |
|
PubMed search |
[1] |
[2] |
|
|
C-fos-induced growth factor (FIGF) (or vascular endothelial growth factor D, VEGF-D) is a vascular endothelial growth factor that in humans is encoded by the FIGF gene.[1]
The protein encoded by this gene is a member of the platelet-derived growth factor/vascular endothelial growth factor (PDGF/VEGF) family and is active in angiogenesis, lymphangiogenesis, and endothelial cell growth. This secreted protein undergoes a complex proteolytic maturation, generating multiple processed forms that bind and activate VEGFR-2 and VEGFR-3 receptors. The structure and function of this protein is similar to those of vascular endothelial growth factor C.[1]
Tumor metastasis to lymph nodes:
Lymph node metastasis is very often associated with several types of human malignancies. Cancer cells’ journey to lymph node takes place largely through lymphatic tunnel located in and around of primary tumor. VEGF-D’s interactions with VEGFR-3 predominantly expressed in lymphatic vessels plays a key role in restructuring lymphatic channel and, hence, able to alter its functions related to fluid and cell transport along the conduits. VEGF-D has been established to be over-expressed in both tumor tissues and patients’ serum samples in several types of human cancer. In addition, VEGF-D expression has been implicated with increased incidence of regional lymph node metastasis. In experimental mice study, genetically modified tumor cell that was forced to produce VEGF-D protein have been established to boost up regional lymph nodes metastases.[2]
References
- ^ a b "Entrez Gene: FIGF c-fos induced growth factor (vascular endothelial growth factor D)".
- ^ VEGF-D promotes the metastatic spread of tumor cells... [Nat Med. 2001] - PubMed - NCBI
Further reading
- Maruyama K; Sugano S (1994). "Oligo-capping: a simple method to replace the cap structure of eukaryotic mRNAs with oligoribonucleotides". Gene 138 (1–2): 171–4. doi:10.1016/0378-1119(94)90802-8. PMID 8125298.
- Orlandini M; Marconcini L; Ferruzzi R; Oliviero S (1996). "Identification of a c-fos-induced gene that is related to the platelet-derived growth factor/vascular endothelial growth factor family". Proc. Natl. Acad. Sci. U.S.A. 93 (21): 11675–80. doi:10.1073/pnas.93.21.11675. PMC 38117. PMID 8876195.
- Yamada Y; Nezu J; Shimane M; Hirata Y (1997). "Molecular cloning of a novel vascular endothelial growth factor, VEGF-D". Genomics 42 (3): 483–8. doi:10.1006/geno.1997.4774. PMID 9205122.
- Suzuki Y; Yoshitomo-Nakagawa K; Maruyama K et al. (1997). "Construction and characterization of a full length-enriched and a 5'-end-enriched cDNA library". Gene 200 (1–2): 149–56. doi:10.1016/S0378-1119(97)00411-3. PMID 9373149.
- Achen MG; Jeltsch M; Kukk E et al. (1998). "Vascular endothelial growth factor D (VEGF-D) is a ligand for the tyrosine kinases VEGF receptor 2 (Flk1) and VEGF receptor 3 (Flt4)". Proc. Natl. Acad. Sci. U.S.A. 95 (2): 548–53. doi:10.1073/pnas.95.2.548. PMC 18457. PMID 9435229.
- Rocchigiani M; Lestingi M; Luddi A et al. (1998). "Human FIGF: cloning, gene structure, and mapping to chromosome Xp22.1 between the PIGA and the GRPR genes". Genomics 47 (2): 207–16. doi:10.1006/geno.1997.5079. PMID 9479493.
- Stacker SA; Stenvers K; Caesar C et al. (1999). "Biosynthesis of vascular endothelial growth factor-D involves proteolytic processing which generates non-covalent homodimers". J. Biol. Chem. 274 (45): 32127–36. doi:10.1074/jbc.274.45.32127. PMID 10542248.
- Strausberg RL; Feingold EA; Grouse LH et al. (2003). "Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences". Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899–903. doi:10.1073/pnas.242603899. PMC 139241. PMID 12477932.
- Nakamura Y; Yasuoka H; Tsujimoto M et al. (2003). "Prognostic significance of vascular endothelial growth factor D in breast carcinoma with long-term follow-up". Clin. Cancer Res. 9 (2): 716–21. PMID 12576440.
- Yokoyama Y; Charnock-Jones DS; Licence D et al. (2003). "Vascular endothelial growth factor-D is an independent prognostic factor in epithelial ovarian carcinoma". Br. J. Cancer 88 (2): 237–44. doi:10.1038/sj.bjc.6600701. PMC 2377043. PMID 12610509.
- Rissanen TT; Markkanen JE; Gruchala M et al. (2003). "VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses". Circ. Res. 92 (10): 1098–106. doi:10.1161/01.RES.0000073584.46059.E3. PMID 12714562.
- Funaki H; Nishimura G; Harada S et al. (2003). "Expression of vascular endothelial growth factor D is associated with lymph node metastasis in human colorectal carcinoma". Oncology 64 (4): 416–22. doi:10.1159/000070301. PMID 12759540.
- Orlandini M; Semboloni S; Oliviero S (2004). "Beta-catenin inversely regulates vascular endothelial growth factor-D mRNA stability". J. Biol. Chem. 278 (45): 44650–6. doi:10.1074/jbc.M304255200. PMID 12920128.
- McColl BK; Baldwin ME; Roufail S et al. (2003). "Plasmin Activates the Lymphangiogenic Growth Factors VEGF-C and VEGF-D". J. Exp. Med. 198 (6): 863–8. doi:10.1084/jem.20030361. PMC 2194198. PMID 12963694.
- Gerhard DS; Wagner L; Feingold EA et al. (2004). "The Status, Quality, and Expansion of the NIH Full-Length cDNA Project: The Mammalian Gene Collection (MGC)". Genome Res. 14 (10B): 2121–7. doi:10.1101/gr.2596504. PMC 528928. PMID 15489334.
- Vlahakis NE; Young BA; Atakilit A; Sheppard D (2005). "The lymphangiogenic growth factors VEGF-C and D are ligands for the integrin α9β1". J. Biol. Chem. 280 (6): 4544–52. doi:10.1074/jbc.M412816200. PMC 1368959. PMID 15590642.
- Kurahara H; Takao S; Maemura K et al. (2005). "Impact of vascular endothelial growth factor-C and -D expression in human pancreatic cancer: its relationship to lymph node metastasis". Clin. Cancer Res. 10 (24): 8413–20. doi:10.1158/1078-0432.CCR-04-0379. PMID 15623620.
- Fink AM; Kaltenegger I; Schneider B et al. (2005). "Serum level of VEGF-D in patients with primary lymphedema". Lymphology 37 (4): 185–9. PMID 15693535.
- Kaushal V; Mukunyadzi P; Dennis RA et al. (2005). "Stage-specific characterization of the vascular endothelial growth factor axis in prostate cancer: expression of lymphangiogenic markers is associated with advanced-stage disease". Clin. Cancer Res. 11 (2 Pt 1): 584–93. PMID 15701844.
- Yasuoka H; Nakamura Y; Zuo H et al. (2005). "VEGF-D expression and lymph vessels play an important role for lymph node metastasis in papillary thyroid carcinoma". Mod. Pathol. 18 (8): 1127–33. doi:10.1038/modpathol.3800402. PMID 15803188.
Growth factors
|
|
Fibroblast |
FGF receptor ligands: |
- FGF1/FGF2/FGF5
- FGF3/FGF4/FGF6
|
|
KGF |
- FGF7/FGF10/FGF22
- FGF8/FGF17/FGF18
- FGF9/FGF16/FGF20
|
|
FGF homologous factors: |
|
|
hormone-like: |
|
|
|
EGF-like domain |
|
|
TGFβ pathway |
|
|
Insulin-like |
|
|
Platelet-derived |
|
|
Vascular endothelial |
- VEGF-A
- VEGF-B
- VEGF-C
- VEGF-D
- PGF
|
|
Other |
|
|
Index of signal transduction
|
|
Description |
- Intercellular
- neuropeptides
- growth factors
- cytokines
- hormones
- Cell surface receptors
- ligand-gated
- enzyme-linked
- G protein-coupled
- immunoglobulin superfamily
- integrins
- neuropeptide
- growth factor
- cytokine
- Intracellular
- adaptor proteins
- GTP-binding
- MAP kinase
- Calcium signaling
- Lipid signaling
- Pathways
- hedgehog
- Wnt
- TGF beta
- MAPK ERK
- notch
- JAK-STAT
- apoptosis
- hippo
- TLR
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- VEGF-D as a Marker in the Aid of Malignant Metastatic Pleural Effusion Diagnosis.
- Maa HC1, Chao TT, Wang CY, Pei D, Liang YJ, Chen YL.
- Applied immunohistochemistry & molecular morphology : AIMM / official publication of the Society for Applied Immunohistochemistry.Appl Immunohistochem Mol Morphol.2014 Sep 15. [Epub ahead of print]
- BACKGROUND:: The sensitivity in cytology diagnosis of malignant metastatic pleural effusion (MMPE) is insufficient nowadays due to the similarity of the reactive mesothelial cells and malignant cells. Vascular endothelial growth factor (VEGF) is one of the key factors in tumor lymphangiogenesis and
- PMID 25221955
- Evaluation of the Extent of Pulmonary Cysts and Their Association with Functional Variables and Serum Markers in Lymphangioleiomyomatosis (LAM).
- Baldi BG1, Araujo MS, Freitas CS, da Silva Teles GB, Kairalla RA, Dias OM, Pereira DA, Pimenta SP, Carvalho CR.
- Lung.Lung.2014 Sep 9. [Epub ahead of print]
- PURPOSE: Although computed tomography (CT) has been used previously to assess disease severity in lymphangioleiomyomatosis (LAM), the associations between the extent of pulmonary cysts on CT and six-minute walk test (6MWT), matrix metalloproteinases (MMPs) and vascular endothelial growth factor (VEG
- PMID 25201087
- Evidence for pericyte origin of TSC-associated renal angiomyolipomas and implications for angiotensin receptor inhibition therapy.
- Siroky BJ1, Yin H2, Dixon BP1, Reichert RJ1, Hellmann AR3, Ramkumar T4, Tsuchihashi Z5, Bunni M6, Dillon J6, Bell PD6, Sampson JR7, Bissler JJ8.
- American journal of physiology. Renal physiology.Am J Physiol Renal Physiol.2014 Sep 1;307(5):F560-70. doi: 10.1152/ajprenal.00569.2013. Epub 2014 Jun 11.
- Nearly all patients with tuberous sclerosis complex (TSC) develop renal angiomyolipomas, although the tumor cell of origin is unknown. We observed decreased renal angiomyolipoma development in patients with TSC2- polycystic kidney disease 1 deletion syndrome and hypertension that were treated from a
- PMID 24920756
Japanese Journal
- High Expression of HuR in Cytoplasm, but Not Nuclei, Is Associated with Malignant Aggressiveness and Prognosis in Bladder Cancer
- Miyata Yasuyoshi,Watanabe Shin-ichi,Sagara Yuji,Mitsunari Kensuke,Matsuo Tomohiro,Ohba Kojiro,Sakai Hideki
- PLoS ONE 8(3), e59095, 2013-03-13
- … The main objective of this investigation was to clarify the relationships between HuR expression and clinical significance and cancer cell proliferation, angiogenesis, lymphangiogenesis, and expressions of cyclooxygenase (COX)-2 and vascular endothelial growth factor (VEGF)-A, -C, and -D. …
- NAID 120005231143
- Lymphatic vessel density and vascular endothelial growth factor expression in squamous cell carcinomas of lip and oral cavity: a clinicopathological analysis with immunohistochemistry using antibodies to D2-40, VEGF-C and VEGF-D
- Watanabe Soh,Kato Masako,Kotani Isamu,Ryoke Kazuo,Hayashi Kazuhiko
- Yonago Acta medica 56(1), 29-37, 2013-03-00
- NAID 120005263095
- Lymphangiogenesis in regional lymph nodes predicts nodal recurrence in pathological N0 squamous cell carcinoma of the tongue
- Hirota Kyoko,Wakisaka Naohiro,Sawada-Kitamura Seiko,Kondo Satoru,Endo Kazuhira,Tsuji Akira,Murono Shigeyuki,Yoshizaki Tomokazu
- Histopathology 61(6), 1065-1071, 2012-12-00
- … Primary tumour sections were examined for the expression of lymphangiogenic factors: vascular endothelial growth factor (VEGF)-C and VEGF-D. … Simultaneous increases in VEGF-C and VEGF-D expression were significantly associated with both an increase in LVC in regional lymph nodes (P=0.0001) and a decrease in the rate of survival without nodal recurrence (P=0.016). …
- NAID 120004754705
Related Links
- ... -CはVEGFR-2、VEGFR-3およびニューロピリン-2を、VEGF-DはVEGFR-2およびVEGFR-3を受容体とします。VEGF-C,-DはVEGFR-3を介してリンパ管新生を誘導する作用があり、がんのリンパ節転移に関与します。 PDFリンク ...
- The onset of angiogenesis is believed to be an early event in tumorigenesis and may facilitate tumor progression and metastasis. Several growth factors with angiogenic activity have been described. These include fibroblast growth ...
Related Pictures
![Human VEGF-D Quantikine ELISA Kit: R&D](https://1mg.info/0/b/l/0148.jpg)
![Lymphangiogenic growth factor-endothelial](https://1mg.info/0/b/l/0149.jpg)
![漆【乙烯基玻璃鳞片面漆VEGF-D](https://1mg.info/0/b/l/0150.jpg)
![VEGF-D (H-144): sc-13085. Western blot](https://1mg.info/0/b/l/0151.jpg)
![VEGF-D Promotes Tumor Metastasis by](https://1mg.info/0/b/l/0153.jpg)
★リンクテーブル★
[★]
- 英
- vascular endothelial growth factor D、VEGF-D
- 関
- 血管内皮細胞増殖因子D
[★]
血管内皮増殖因子D、血管内皮細胞増殖因子D
- 関
- VEGF-D
[★]
[★]
血管内皮増殖因子 vascular endothelial growth factor